XIAFLEX® helps disrupt 2 collagen types within a Peyronie's plaque1
- At higher doses and longer incubation times, nonfibrillar type IV collagen was affected causing collagen lysis in small veins1
- Did not cause structural damage to arteries, nerves, or large veins that contain type IV collagen in in vitro or in vivo studies1
- There are no clinical data regarding the relative contributions of the individual collagenases to the efficacy of
XIAFLEX®in the treatment of Peyronie’s disease1
AUA Peyronie's disease treatment guideline for
In 2015, the American Urological Association (AUA) published a guideline that provides a clinical framework for the diagnosis and treatment of Peyronie's disease. The following guideline statements are specific to
Clinicians may administer intralesional collagenase clostridium histolyticum in combination with modeling by the clinician and by the patient for the reduction of penile curvature in patients with stable Peyronie's disease, penile curvature >30° and <90°, and intact erectile function (with or without the use of medications). (Moderate Recommendation; Evidence Strength Grade B)2
Clinicians should counsel patients with Peyronie's disease prior to beginning treatment with intralesional collagenase regarding potential occurrence of adverse events, including penile ecchymosis, swelling, pain, and corporal rupture. (Clinical Principle)2
- Moderate Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate2
- Body of Evidence Strength Grade B in support of a Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances but that better evidence could change confidence2
A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature.2
What does treatment with
XIAFLEX® consist of?
A treatment course of
XIAFLEX® takes ~24 weeks and consists of up to 4 treatment cycles approximately 6 weeks apart1
If the curvature deformity is less than 15 degrees after the first, second, or third treatment cycle, or if further treatment is not clinically indicated, then subsequent treatment cycles should not be administered.1
The safety of more than one treatment course of
Each treatment cycle involves1:
- 3 office visits over the course of 3–7 days
- Each cycle begins with the injection of
XIAFLEX®into the palpable Peyronie's plaque
- The second injection is performed 1–3 days later after the first injection
- Based on patient's penile swelling, you can assess if he is ready for the second injection
- In-office modeling is performed 1–3 days after the second injection
- The patient then performs at-home daily penile modeling for approximately 6 weeks
XIAFLEX® treatment procedure
Penile modeling: Helps reduce erectile curvature and straighten the penile shaft1
Offer patients a guide for treatment and at-home modeling
Storage & preparation of
Store in refrigerator (36°F to 46°F; 2°C to 8°C).
Do not freeze. Ensure both vials are upright prior to refrigerating.
Can be kept at room temperature (68°F to 77°F; 20°C to 25°C) for up to 1 hour or refrigerate (36°F to 46°F; 2°C to 8°C) for up to 4 hours prior to administration.
If refrigerated, let stand at room temperature for approximately 15 minutes before use.